Zobrazeno 1 - 10
of 23
pro vyhledávání: '"John Cogswell"'
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e54415 (2013)
The causal role of the hedgehog pathway in cancer has been best documented in basal cell carcinoma of the skin. To assess potential DNA alterations of the hedgehog pathway in gastric cancer, we sequenced SMO and PTCH1 genes in a set of 39 gastric tum
Externí odkaz:
https://doaj.org/article/2940382625a84b8f9212aa9427b6e19d
Autor:
Wenqin Feng, Ryotaku Inoue, Takeshi Kuwata, Naoki Niikura, Satoshi Fujii, Nobue Kumaki, Kokichi Honda, Li-An Xu, Aaron Goetz, Patricia Gaule, John Cogswell, David L. Rimm, Robert McGee
Publikováno v:
Applied Immunohistochemistry & Molecular Morphology. 31:339-345
Autor:
Joan M. Carboni, Jeffrey Jackson, Friedrich G. Finckenstein, Tai W. Wong, Rolf-Peter Ryseck, Craig Fairchild, Zhenhao Qi, Dharmesh Patel, John Cogswell, Warren Hurlburt, Karen A. Reeves, Stephen Hillerman, Ann Greer, Han Chang, Fei Huang
Supplementary Tables S1-S4. Supplementary Table S1: Association of gene mutations, IRS2 copy number gain, and gene expression level with in vitro sensitivity to BMS-754807 in 60 CRC cell lines. Supplementary Table S2: The relationship between KRAS, B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faf361093d6982b4e2b58d163680e344
https://doi.org/10.1158/1535-7163.22503652.v1
https://doi.org/10.1158/1535-7163.22503652.v1
Autor:
Joan M. Carboni, Jeffrey Jackson, Friedrich G. Finckenstein, Tai W. Wong, Rolf-Peter Ryseck, Craig Fairchild, Zhenhao Qi, Dharmesh Patel, John Cogswell, Warren Hurlburt, Karen A. Reeves, Stephen Hillerman, Ann Greer, Han Chang, Fei Huang
Supplementary Figures S1-S5. Supplementary Figure S1. Similarity of CNV profiles are seen from both CRC cell lines and CRC primary tumor samples with highlight on chromosome 13 copy number gain. Supplementary Figure S2: The RNA expression levels comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2952872ef51281f0ac1ebaa8a0d3bbc8
https://doi.org/10.1158/1535-7163.22503658.v1
https://doi.org/10.1158/1535-7163.22503658.v1
Autor:
John Cogswell, Patrik Vitazka, Keyur Desai, Byron Lawson, Sid P. Kerkar, Mark Stern, Lisu Wang, Zhenhao Qi
Publikováno v:
The Journal of Molecular Diagnostics. 21:796-807
Clinical biomarker studies are often hindered by the scarcity or suboptimal quality of biological specimens. EdgeSeq, a transcriptomics analysis platform, combines quantitative nuclease protection assay technology with next-generation sequencing, usi
Publikováno v:
Bioanalysis. 8:2305-2316
Aim: Formalin-fixed, paraffin-embedded (FFPE) clinical tissue samples have the potential to provide valuable gene-expression data for the development of cancer biomarkers. However, FFPE RNA is extensively fragmented, presenting a significant challeng
Autor:
Andrew S. Luksik, Eileen Kim, Russell Maxwell, Drew M. Pardoll, Michael Lim, Christopher M. Jackson, Zineb Belcaid, Pina M. Cardarelli, Alice Hung, Debebe Theodros, Tomas Garzon-Muvdi, Miho Oyasu, John Cogswell, Dimitrios Mathios, Yuanxuan Xia, Adela Wu, Henry Brem
Publikováno v:
Journal of neuro-oncology. 143(2)
Emerging evidence suggests that myeloid cells play a critical role in glioblastoma (GBM) immunosuppression. Disappointing results of recent checkpoint inhibitor trials suggest that combination immunotherapy with alternative agents could be fruitful i
Autor:
John N. Feder, H. David Inzunza, Diana M. Cardona, John Cogswell, James Novotny, Gabe Mintier, Qiuyan Wu
Publikováno v:
Molecular Diagnosis & Therapy
Aim Nivolumab, a fully human immunoglobulin G4 programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has activity in melanoma, non–small-cell lung cancer (NSCLC), renal cell carcinoma (RCC), and Hodgkin lymphoma. Nivolumab is approved in
Autor:
Pauline Simmons, Emin Oroudjev, Ilana Satnick, Gregory Cherryholmes, Betsy O. Spaulding, Malinka Jansson, Henrik Winther, Molly M. Millett, John Cogswell, Xiaoling Zhang, Clive R. Taylor, Rachel Cleveland, Josette William, Josette Carnahan, James Novotny, Therese Phillips, H. David Inzunza
Publikováno v:
Applied Immunohistochemistry & Molecular Morphology
Nivolumab is a monoclonal antibody that blocks the interaction between programmed cell death 1 (PD1) and programmed cell death 1-ligand 1 (PD-L1), resulting in enhanced antitumor activity by the immune system. Nivolumab is currently approved by the U
Autor:
Xiaoling Zhang, James Novotny, Pauline Simmons, Therese Phillips, Hector D. Inzunza, John Cogswell, Clive R. Taylor
Publikováno v:
Applied Immunohistochemistry & Molecular Morphology
Supplemental Digital Content is available in the text.
Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune checkpoint inhibitor antibody, developed by Bristol-Myers Squibb Inc., has activity across non–small cell lung cancer (NSCLC)
Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune checkpoint inhibitor antibody, developed by Bristol-Myers Squibb Inc., has activity across non–small cell lung cancer (NSCLC)